Latest news
ZYME Maintained by Truist Securities -- Price Target Raised to $32.00 - GuruFocusGuruFocus · Fri, 07 Aug 2026 16:34:03 GMTCGNX Maintains Rating by Truist Securities -- Price Target Raised to $78 - GuruFocusGuruFocus · Fri, 07 Aug 2026 15:37:34 GMTFIVE9, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $35 FROM $23 - MoomooMoomoo · Fri, 07 Aug 2026 13:24:39 GMTMOTOROLA : TRUIST SECURITIES RAISES TARGET PRICE TO $545 FROM $525 - BitgetBitget · Fri, 07 Aug 2026 12:25:05 GMTSOMNIGROUP INTERNATIONAL INC. : TRUIST SECURITIES CUTS TARGET PRICE TO $100 FROM $115 - BitgetBitget · Fri, 07 Aug 2026 11:59:32 GMTPARKER-HANNIFIN CORP : TRUIST SECURITIES RAISES TARGET PRICE TO $1358 FROM $1269 - BitgetBitget · Fri, 07 Aug 2026 11:58:21 GMTALBEMARLE : TRUIST SECURITIES CUTS TARGET PRICE TO $225 FROM $245 - BitgetBitget · Fri, 07 Aug 2026 11:58:09 GMTHALOZYME THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TO OUTPERFORM FROM MARKET PERFORM; RAISES TARGET PRICE TO $110 FROM $83 - BitgetBitget · Fri, 07 Aug 2026 11:57:20 GMT